The quantification of Bcr-Abl transcript numbers in chronic myelogenous leukemia (CML) patients described here uses simultaneous competitive PCR amplification of the target gene (Bcr-Abl) and a reference gene (porphobilinogen deaminase; Pbgd) together with a single composite competitor molecule for both targets based on heterologous sequences. Using this technique, Bcr-Abl transcript numbers could be reproducibly determined even in clinical samples known to harbour poor quality RNA.
No takes yet. Share an insight, caveat, or question.
Stefan Nagel (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: